pentamidine has been researched along with Keratitis, Acanthamoeba in 8 studies
Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.
pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Acanthamoeba castellanii genotype T4 was obtained from a patient with keratitis and subjected to in vitro susceptibility testing with various antimicrobial agents, including Chlorhexidine (CHX), Pentamidine isethionate (PI)Polyhexamethylene biguanide (PHMB), and Miltefosine to assess their efficacy against Acanthamoeba trophozoites and cyst." | 8.31 | Comparing cytotoxicity and efficacy of miltefosine and standard antimicrobial agents against Acanthamoeba trophozoites and cyst forms: An in vitro study. ( Kazemirad, E; Latifi, A; Mohebali, M; Rezaian, M; Soleimani, M; Yasami, S, 2023) |
| "The aim of this study was to evaluate the outcome of pretreatment of Acanthamoeba keratitis with intravenous pentamidine (IVP) before therapeutic keratoplasty (TKP)." | 7.81 | Treatment of acanthamoeba keratitis with intravenous pentamidine before therapeutic keratoplasty. ( Goins, KM; Greiner, MA; Kitzmann, AS; Sacher, BA; Sutphin, JE; Wagoner, MD, 2015) |
| "For example, current treatment against Acanthamoeba keratitis requires early diagnosis followed by hourly topical application of a mixture of drugs that can last up to a year." | 5.34 | Cellulose biosynthesis pathway is a potential target in the improved treatment of Acanthamoeba keratitis. ( Alsam, S; Dudley, R; Khan, NA, 2007) |
| " Acanthamoeba castellanii genotype T4 was obtained from a patient with keratitis and subjected to in vitro susceptibility testing with various antimicrobial agents, including Chlorhexidine (CHX), Pentamidine isethionate (PI)Polyhexamethylene biguanide (PHMB), and Miltefosine to assess their efficacy against Acanthamoeba trophozoites and cyst." | 4.31 | Comparing cytotoxicity and efficacy of miltefosine and standard antimicrobial agents against Acanthamoeba trophozoites and cyst forms: An in vitro study. ( Kazemirad, E; Latifi, A; Mohebali, M; Rezaian, M; Soleimani, M; Yasami, S, 2023) |
| "The aim of this study was to evaluate the outcome of pretreatment of Acanthamoeba keratitis with intravenous pentamidine (IVP) before therapeutic keratoplasty (TKP)." | 3.81 | Treatment of acanthamoeba keratitis with intravenous pentamidine before therapeutic keratoplasty. ( Goins, KM; Greiner, MA; Kitzmann, AS; Sacher, BA; Sutphin, JE; Wagoner, MD, 2015) |
| " Medical management comprises prolonged empiric treatment with multiple drugs, leading to adverse effects and suboptimal cure." | 1.72 | Evaluation of in vitro activity of five antimicrobial agents on Acanthamoeba isolates and their toxicity on human corneal epithelium. ( Gupta, A; Khurana, S; Megha, K; Sehgal, R; Sharma, C; Sharma, M, 2022) |
| "Acanthamoeba keratitis was diagnosed on microbiological culture in 94 eyes (48." | 1.40 | The impact of topical corticosteroid use before diagnosis on the outcome of Acanthamoeba keratitis. ( Carnt, N; Dart, JK; Minassian, DC; Robaei, D, 2014) |
| "For example, current treatment against Acanthamoeba keratitis requires early diagnosis followed by hourly topical application of a mixture of drugs that can last up to a year." | 1.34 | Cellulose biosynthesis pathway is a potential target in the improved treatment of Acanthamoeba keratitis. ( Alsam, S; Dudley, R; Khan, NA, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Megha, K | 1 |
| Sharma, M | 1 |
| Sharma, C | 1 |
| Gupta, A | 1 |
| Sehgal, R | 1 |
| Khurana, S | 1 |
| Latifi, A | 1 |
| Mohebali, M | 1 |
| Yasami, S | 1 |
| Soleimani, M | 1 |
| Rezaian, M | 1 |
| Kazemirad, E | 1 |
| Papa, V | 1 |
| Rama, P | 1 |
| Radford, C | 1 |
| Minassian, DC | 2 |
| Dart, JKG | 1 |
| Shi, L | 1 |
| Stachon, T | 1 |
| Seitz, B | 1 |
| Wagenpfeil, S | 1 |
| Langenbucher, A | 1 |
| Szentmáry, N | 1 |
| Alfonso-Muñoz, EA | 1 |
| Roig-Revert, MJ | 1 |
| Fernández-López, E | 1 |
| Hernández-Díaz, M | 1 |
| Araujo-Miranda, R | 1 |
| Peris-Martínez, C | 1 |
| Robaei, D | 1 |
| Carnt, N | 1 |
| Dart, JK | 1 |
| Sacher, BA | 1 |
| Wagoner, MD | 1 |
| Goins, KM | 1 |
| Sutphin, JE | 1 |
| Greiner, MA | 1 |
| Kitzmann, AS | 1 |
| Dudley, R | 1 |
| Alsam, S | 1 |
| Khan, NA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Active-Controlled, Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of 0.08% PHMB Ophthalmic Solution in Comparison With 0.02% PHMB + 0.1% Propamidine Combination Therapy in Subjects Affected by Acanthamoeba Keratitis[NCT03274895] | Phase 3 | 135 participants (Actual) | Interventional | 2017-08-13 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of patients cured 30 days after discontinuing all study therapies, within 12 months of randomization (NCT03274895)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| PHMB 0.08% Plus Placebo | 84.8 |
| PHMB 0.02% Plus Propamidine 0.1% | 88.5 |
Time needed to reach a clinical resolution (NCT03274895)
Timeframe: maximum 12 months
| Intervention | days (Median) |
|---|---|
| PHMB 0.08% Plus Placebo | 140 |
| PHMB 0.02% Plus Propamidine 0.1% | 114 |
Final visual acuity (best corrected) (NCT03274895)
Timeframe: maximum 12 months
| Intervention | LogMAR (Median) |
|---|---|
| PHMB 0.08% Plus Placebo | 0.000 |
| PHMB 0.02% Plus Propamidine 0.1% | 0.000 |
8 other studies available for pentamidine and Keratitis, Acanthamoeba
| Article | Year |
|---|---|
Evaluation of in vitro activity of five antimicrobial agents on Acanthamoeba isolates and their toxicity on human corneal epithelium.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Anti-Infective Agents; Chlorhexidine; Epithelium, Corneal; Flu | 2022 |
Comparing cytotoxicity and efficacy of miltefosine and standard antimicrobial agents against Acanthamoeba trophozoites and cyst forms: An in vitro study.
Topics: Acanthamoeba; Acanthamoeba Keratitis; Animals; Anti-Infective Agents; Chlorhexidine; Chlorocebus aet | 2023 |
Topics: Acanthamoeba Keratitis; Adolescent; Adult; Aged; Antiprotozoal Agents; Biguanides; Chlorhexidine; Di | 2020 |
The Effect of Antiamoebic Agents on Viability, Proliferation and Migration of Human Epithelial Cells, Keratocytes and Endothelial Cells, In Vitro.
Topics: Acanthamoeba Keratitis; Anti-Infective Agents; Antiprotozoal Agents; Benzamidines; Cell Count; Cell | 2018 |
A report of 10 patients with Acanthamoeba keratitis.
Topics: Acanthamoeba Keratitis; Adolescent; Amebicides; Biguanides; Child; Conjunctivitis; Contact Lenses; C | 2018 |
The impact of topical corticosteroid use before diagnosis on the outcome of Acanthamoeba keratitis.
Topics: Acanthamoeba Keratitis; Administration, Topical; Adolescent; Adult; Antiprotozoal Agents; Biguanides | 2014 |
Treatment of acanthamoeba keratitis with intravenous pentamidine before therapeutic keratoplasty.
Topics: Acanthamoeba Keratitis; Adolescent; Adult; Antiprotozoal Agents; Female; Graft Survival; Humans; Inf | 2015 |
Cellulose biosynthesis pathway is a potential target in the improved treatment of Acanthamoeba keratitis.
Topics: Acanthamoeba castellanii; Acanthamoeba Keratitis; Amebicides; Animals; Brain; Cells, Cultured; Cellu | 2007 |